ClinicalTrials.gg
CompletedNCT01970540Updated Mar 9, 2020Results posted

Study Escalating Doses of PM01183 in Combination With Fixed Doxorubicin in Patients With Specific Advanced Unresectable Solid Tumors

A Phase 1 interventional study of lurbinectedin (PM01183) and Doxorubicin in Endometrial Adenocarcinomas, Neuroendocrine Tumors and Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy, sponsored by PharmaMar. Completed at 7 sites in 2 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2020-03-09.

Sponsored by PharmaMar · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 4 months after the study started (first participant enrolled May 2011, registered Oct 2013).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
122
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 43 studies in Neuroendocrine Tumors with a site in Spain — 9 open to participants now, 16 under way, 7 of them phase 3. Neuroendocrine Tumors · Spain.

Enrollment
22nd of 37
122 · median 141
Started
2011
with 3 others
Phase 1
2 of 43
1 open now
Registered
15th of 43
by date
Lead sponsor
2 of 43
PharmaMar

Among the 43 studies in Neuroendocrine Tumors with a site in Spain, this one is the 22nd largest by enrollment of the 37 interventional ones that give a count, is one of 4 that started in 2011, is one of 2 in phase 1, and was the 15th registered.

Neuroendocrine Tumors

543 studies on the registry are indexed under Neuroendocrine Tumors; 135 are open to participants now.

Browse Neuroendocrine Tumors studies →

Open to participants now

9 of the 43 studies in Neuroendocrine Tumors with a site in Spain are open now. Recruiting first, the newest first:

4 more — sign in →

All 9 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 112 Neuroendocrine Tumors studies recruiting now, 73 (65%) set no upper age limit and 17 (15%) stop at 75 or younger; 12 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies in Neuroendocrine Tumors with a site in Spain, or all of them as a file.
02

Study summary

Phase I Multicenter, Open-label, Clinical and Pharmacokinetic Study of PM01183 in Combination with Fixed Doxorubicin in Non- Heavily Pretreated Patients with Selected Advanced Solid Tumors to determine the maximum tolerated dose (MTD) and the recommended dose (RD) of PM01183 in combination with doxorubicin, to characterize the safety profile and feasibility of this combination, to characterize the pharmacokinetics (PK) of this combination, to obtain preliminary information on the clinical antitumor activity,to explore the feasibility, safety and efficacy of a potential improvable dose of this combination in selected tumor types [i.e. small cell lung cancer (SCLC) and endometrial cáncer] and to evaluate the pharmacogenomics (PGx) in tumor samples of patients exposed to PM01183 and doxorubicin at the RD in order to assess potential markers of response and/or resistance.

Read the detailed description

The study has currently met its primary end point and is now recruiting patients to be treated at the RD expansion cohort of selected tumor types, specifically: endometrial adenocarcinomas, neuroendocrine tumors, and small-cell lung cancer (SCLC).

03

Conditions studied

  • Endometrial Adenocarcinomas
  • Neuroendocrine Tumors
  • Small-cell Lung Cancer With Less Than 2 Prior Cytotoxic-containing Lines of Therapy

Keywords

  • lurbinectedin
  • PM01183
  • tumors
  • cancer
  • Pharma Mar
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Voluntarily written
  • Age: between 18 and 75 years (both inclusive).
  • (ECOG) performance status (PS) ≤ 1. Cohort of patients with SCLC and endometrial cáncer ECOG PS ≤ 2.
  • ≥ 3 months.
  • Patients with a histologically/ confirmed diagnosis of advanced disease of any of the following tumors:

    1. Breast cancer
    2. Soft-tissue sarcoma
    3. Primary bone sarcomas.
    4. Gynecologic tumors (endometrial adenocarcinomas, epithelial ovarian cancer...)
    5. Hepatocellular carcinoma
    6. Gastroenteropancreatic neuroendocrine tumors
    7. Small cell lung cancer (SCLC)
    8. Gastric cancer
    9. Bladder cancer
    10. Adenocarcinoma of unknown primary site
  • At least three weeks since the last anticancer therapy, including radiotherapy
  • Adequate bone marrow, renal, hepatic, and metabolic function
  • (LVEF) by echocardiogram (ECHO) or multiple-gated acquisition (MUGA) scan within normal range (according to institutional standards).
  • Women of must have a negative serum pregnancy test before study entry. Both women and men must agree to use a medically acceptable method of throughout the treatment period and for six weeks after discontinuation of treatment

Exclusion criteria

Exclusion Criteria:

  • Concomitant diseases/conditions:

    • History or presence of unstable angina, myocardial infarction, congestive heart failure, or valvular heart disease within last year.
    • Symptomatic or any uncontrolled arrhythmia
    • Ongoing chronic alcohol consumption, or cirrhosis
    • Active uncontrolled infection.
    • Known (HIV) infection.
    • Any other major illness that, in the Investigator's judgment
  • or involvement.
  • Men or women of who are not using an effective method of
  • Patients who have had radiation therapy in more than 35% of the bone marrow. This criterion will not apply to cohort of patients with SCLC and endometrial cáncer.
  • History of previous bone marrow and/or stem cell transplantation.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    lurbinectedin (PM01183) / doxorubicin

    Drug: lurbinectedin (PM01183) · Drug: Doxorubicin

Interventions

  • lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials.

  • Commercially available presentations of vials containing doxorubicin will be provided as appropriate.

06

What researchers measure

Primary outcomes

  1. Maximum Tolerated Dose (MTD)

    A minimum of three patients will be included at each DL. If no patients experience a DLT during Cycle 1, the dose will be escalated. If one of three patients experiences a DLT, three additional patients will be included at that level. If \>1 evaluable patient during dose escalation at a given DL experience a DLT during Cycle 1, that DL will be considered the MTD and dose escalation will be terminated, except if all DLTs are related to neutropenia exclusively, in which case dose escalation may be resumed as originally planned in a new cohort of patients but with compulsory primary G-CSF prophylaxis.

    Time frame: During the first cycle of treatment, up to 28 days

  2. Recommended Dose (RD)

    The DL immediately below the MTD, or DL4 if the MTD is not yet defined during dose escalation before the last DL (i.e., DL4) is reached, was to be initially expanded up to a minimum of nine evaluable patients. If less than three among the first nine evaluable patients treated within the expansion cohort experience a DLT during Cycle 1, this DL will be the RD.

    Time frame: During the first cycle of treatment, up to 28 days

  3. Number of Participants With Dose-limiting Toxicities

    DLT,dose-limiting toxicity Patients enrolled into this study were originally not allowed to receive primary G-CSF prophylaxis. However, the finding of dose-limiting febrile neutropenia in two patients treated at dose level I in the present study (see below) suggested that increasing doses of the DOX/PM01183 combination might require primary G-CSF prophylaxis to decrease the risk of febrile neutropenia. Therefore, a separate dose escalation was established to define the MTD and the RD of the DOX/PM01183 combination with compulsory primary G-CSF prophylaxis.

    Time frame: During the first cycle of treatment, up to 28 days

Secondary outcomes

  1. Best Overall Tumor Response

    Tumor response was evaluated according to the RECIST v.1.1 for target lesions and assessed by computed tomography (CT) scans or magnetic resonance imagings (MRIs): Progressive disease (PD) is declared when there is an increase in sum of target disease ≥ 20%, stable diease (SD) when the change is \> -30% and ≤ 20%, partial response (PR) when there is a decrease in sum of target disease ≥ 30%, and complete response (CR) when all lesions have disappeared or all lesions have disapeared and all nodal disease is \< 10 mm each.

    Time frame: Tumor assessments were done every six weeks up to study completion

  2. Duration of Response

    The duration of overall response was measured from the time measurement criteria are met for complete response (CR)/ PR, whichever is first recorded, until the first date in which progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) or the date of death. In absence of disease progression or death, the duration of response was censored on the date of last tumor evaluation.

    Time frame: Time from the time measurement criteria are met for complete response, whichever is first recorded, until the first date in which progressive disease is objectively documented or the date of death, assessed up to 72 months

  3. Progression-free Survival

    Progression-free survival (PFS) is defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS was censored on the date of last tumor evaluation.

    Time frame: Time from the date of first administration to the date of PD or death (of any cause), whichever came first, assessed up to 72 months

  4. Overall Survival

    Overall survival (OS) is defined as the time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death were censored at the last date they are known to be alive

    Time frame: Time from the date of first administration to the date of death (of any cause), assessed up to 72 months

07

Results

Posted Mar 9, 2020
Limitations and caveats
None reported

Participant flow

122 patients were enrolled at 7 sites. 120 patients were treated with DOX/PM01183 combination: 73 Cohort A (DOX \[mg/m2\]+PM01183 \[mg FD\]) \& 47 Cohort B (DOX \[mg/m2\]+PM01183 \[mg/m2\]). Patients participated between 25May2011-9Aug2017 (last followup). First dose of the first cycle was given on 13Jun2011 and last dose of the last cycle on 19Jul2017

Participant flow — Overall Study
MilestoneCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
Started732819
Completed000
Not completed732819
Withdrew: Non-treatment-related ae001
Withdrew: Progressive disease552310
Withdrew: Treatment delay over protocol001
Withdrew: Physician decision720
Withdrew: Clinical progression011
Withdrew: End of study202
Withdrew: Adverse event021
Withdrew: Treatment-related ae402
Withdrew: Withdrawal by subject401
Withdrew: Clinical deterioration100

Outcome measures

PrimaryMaximum Tolerated Dose (MTD)

A minimum of three patients will be included at each DL. If no patients experience a DLT during Cycle 1, the dose will be escalated. If one of three patients experiences a DLT, three additional patients will be included at that level. If \>1 evaluable patient during dose escalation at a given DL experience a DLT during Cycle 1, that DL will be considered the MTD and dose escalation will be terminated, except if all DLTs are related to neutropenia exclusively, in which case dose escalation may be resumed as originally planned in a new cohort of patients but with compulsory primary G-CSF prophylaxis.

Time frame:
During the first cycle of treatment, up to 28 days
Reported as:
Number · DOX mg/m2 PM01183 mg FD
Maximum Tolerated Dose (MTD)
DOX mg/m2 PM01183 mg FDPatients Without Primary G-CSF ProphylaxisPatients With Primary G-CSF Prophylaxis
Doxorubicin5050
PM011835.05.0
PrimaryRecommended Dose (RD)

The DL immediately below the MTD, or DL4 if the MTD is not yet defined during dose escalation before the last DL (i.e., DL4) is reached, was to be initially expanded up to a minimum of nine evaluable patients. If less than three among the first nine evaluable patients treated within the expansion cohort experience a DLT during Cycle 1, this DL will be the RD.

Time frame:
During the first cycle of treatment, up to 28 days
Reported as:
Number · DOX mg/m2 PM01183 mg FD
Recommended Dose (RD)
DOX mg/m2 PM01183 mg FDPatients Without Primary G-CSF Prophylaxis
Doxorubicin50
PM011834.0
PrimaryNumber of Participants With Dose-limiting Toxicities

DLT,dose-limiting toxicity Patients enrolled into this study were originally not allowed to receive primary G-CSF prophylaxis. However, the finding of dose-limiting febrile neutropenia in two patients treated at dose level I in the present study (see below) suggested that increasing doses of the DOX/PM01183 combination might require primary G-CSF prophylaxis to decrease the risk of febrile neutropenia. Therefore, a separate dose escalation was established to define the MTD and the RD of the DOX/PM01183 combination with compulsory primary G-CSF prophylaxis.

Time frame:
During the first cycle of treatment, up to 28 days
Reported as:
Count of participants · Participants
Number of Participants With Dose-limiting Toxicities
ParticipantsCohort A: Dose I Without Primary G-CSF ProphylaxisCohort A: Dose II Without Primary G-CSF ProphylaxisCohort A: Dose I Without Primary G-CSF Proph and Age LimitCohort A: Dose III Without Primary G-CSF ProphylaxisCohort A: Dose IV Without Primary G-CSF ProphylaxisCohort A: Dose I With Primary G-CSF ProphylaxisCohort A: Dose III With Primary G-CSF ProphylaxisCohort A: Dose IV With Primary G-CSF ProphylaxisCohort B: DOX [mg/m2] Plus PM01183 [mg/m2]
Number of Participants With Dose-limiting Toxicities200820024
SecondaryBest Overall Tumor Response

Tumor response was evaluated according to the RECIST v.1.1 for target lesions and assessed by computed tomography (CT) scans or magnetic resonance imagings (MRIs): Progressive disease (PD) is declared when there is an increase in sum of target disease ≥ 20%, stable diease (SD) when the change is \> -30% and ≤ 20%, partial response (PR) when there is a decrease in sum of target disease ≥ 30%, and complete response (CR) when all lesions have disappeared or all lesions have disapeared and all nodal disease is \< 10 mm each.

Time frame:
Tumor assessments were done every six weeks up to study completion
Reported as:
Count of participants · Participants
Best Overall Tumor Response
ParticipantsCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
CR710
PR1998
SD≥4 months1344
SD<4 months1163
PD2284
SecondaryDuration of Response

The duration of overall response was measured from the time measurement criteria are met for complete response (CR)/ PR, whichever is first recorded, until the first date in which progressive disease is objectively documented (taking as reference for progressive disease the smallest measurements recorded since the treatment started) or the date of death. In absence of disease progression or death, the duration of response was censored on the date of last tumor evaluation.

Time frame:
Time from the time measurement criteria are met for complete response, whichever is first recorded, until the first date in which progressive disease is objectively documented or the date of death, assessed up to 72 months
Reported as:
Median · months
Duration of Response
monthsCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
Duration of Response7.2 (3.4 to 8.6)5.2 (1 to 6.9)7.5 (6.4 to NA)
SecondaryProgression-free Survival

Progression-free survival (PFS) is defined as the time from the date of first infusion of study treatment to the date of progression or death (due to any cause). If progression or death has not occurred at the time of the analysis, the PFS was censored on the date of last tumor evaluation.

Time frame:
Time from the date of first administration to the date of PD or death (of any cause), whichever came first, assessed up to 72 months
Reported as:
Median · months
Progression-free Survival
monthsCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
Progression-free Survival3.8 (2.6 to 5.3)3.3 (1.4 to 6.2)7.7 (2.0 to 16.7)
SecondaryOverall Survival

Overall survival (OS) is defined as the time from the date of first infusion of study treatment to the date of death (due to any cause). Patients with no documented death were censored at the last date they are known to be alive

Time frame:
Time from the date of first administration to the date of death (of any cause), assessed up to 72 months
Reported as:
Median · months
Overall Survival
monthsCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
Overall Survival36.9 (15.1 to NA)7.9 (4.2 to 11.5)14.2 (4.5 to NA)

Adverse events

Collected over Participants were assessed through study completion, approximately 6 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort A15/73 (20.5%)47/73 (64.4%)73/73 (100%)
Cohort B: SCLC 2nd Line22/28 (78.6%)19/28 (67.9%)28/28 (100%)
Cohort B: Endometrial11/19 (57.9%)14/19 (73.7%)18/19 (94.7%)
Most frequent serious events
Showing 10 of 63
Most frequent serious events
EventCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
Febrile neutropeniaBlood and lymphatic system disorders25/734/284/19
ThrombocytopeniaBlood and lymphatic system disorders7/734/280/19
NeutropeniaBlood and lymphatic system disorders9/732/281/19
Deep vein thrombosisVascular disorders1/730/282/19
VomitingGastrointestinal disorders2/732/281/19
Decreased appetiteMetabolism and nutrition disorders0/732/280/19
HyponatraemiaMetabolism and nutrition disorders0/732/280/19
Lung infectionInfections and infestations0/732/280/19
PneumoniaInfections and infestations3/732/280/19
AnaemiaBlood and lymphatic system disorders4/730/280/19
Most frequent other events
Showing 10 of 119
Most frequent other events
EventCohort ACohort B: SCLC 2nd LineCohort B: Endometrial
FatigueGeneral disorders66/7325/2817/19
NauseaGastrointestinal disorders45/7319/2814/19
Decreased appetiteMetabolism and nutrition disorders44/7316/286/19
AnaemiaBlood and lymphatic system disorders39/737/285/19
AlopeciaSkin and subcutaneous tissue disorders38/737/2810/19
CoughRespiratory, thoracic and mediastinal disorders30/7314/286/19
ConstipationGastrointestinal disorders33/7310/289/19
DiarrhoeaGastrointestinal disorders30/733/289/19
VomitingGastrointestinal disorders26/7312/289/19
Mucosal inflammationGeneral disorders34/735/285/19

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
Age — <=18 years0000
Age — Between 18 and 65 years5318879
Age — >=65 years20101141
Age, Continuous
Age, Continuous(years)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
Median62.2 (22 to 78)64 (49 to 77)66 (55 to 73)62.2 (22 to 78)
Sex: Female, Male
Sex: Female, Male(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
Female3871964
Male3521056
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
Race : Caucasian722719118
Race : Asian/oriental1001
Race : Black0101
ECOG PS
ECOG PS(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
PS 0279642
PS 146191277
PS 20011
Tumor type
Tumor type(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
SCLC 2 line2228050
SCLC 3 line6006
Endometrial1501934
NET-GEP8008
STS8008
Bladder5005
Gastric4004
Breast3003
Ovarian1001
HCC1001
Lines of prior anticancer therapies
Lines of prior anticancer therapies(Participants)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
0 lines120315
1 line42271180
2 lines161522
3 lines2002
>3 lines1001
Body surface area
Body surface area(m^2)Cohort ACohort B: SCLC 2nd LineCohort B: EndometrialTotal
Median1.8 (1.3 to 2.3)1.9 (1.5 to 2.3)1.8 (1.6 to 2.3)1.8 (1.3 to 2.3)

6 further baseline measures are reported on the registry.

08

Study locations

7 sites
  • Hospital Universitari Vall D'Hebron
    Barcelona, 08035, Spain
  • Centro Oncológico Md Anderson International España
    Madrid, 28033, Spain
  • Hospital Ramón Y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundación Jiménez
    Madrid, 28040, Spain
  • Hospital Universitario Madrid Sanchinarro
    Madrid, 28050, Spain
  • Fundación Instituto Valenciano de Oncología
    Valencia, 46009, Spain
  • UCLH (University College London Hospitals)
    London, WC1E 6DB, United Kingdom
09

References and documents

Publications

  • Olmedo ME, Forster M, Moreno V, Lopez-Criado MP, Brana I, Flynn M, Doger B, de Miguel M, Lopez-Vilarino JA, Nunez R, Kahatt C, Cullell-Young M, Zeaiter A, Calvo E. Efficacy and safety of lurbinectedin and doxorubicin in relapsed small cell lung cancer. Results from an expansion cohort of a phase I study. Invest New Drugs. 2021 Oct;39(5):1275-1283. doi: 10.1007/s10637-020-01025-x. Epub 2021 Mar 11. PubMed 33704620 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Aug 2017, 74 months.

Results were first posted in Mar 2020, 2 years 7 months after primary completion.

Of 54 phase 1 interventional studies under Neuroendocrine Tumors, half reached primary completion within 54 months of starting (the median), counting those still running; a quarter within 37 and three quarters within 75. This study's 74 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 22, 2013
First posted
Oct 28, 2013
StartActual
May 25, 2011
Primary completionActual
Aug 9, 2017
CompletionActual
Aug 9, 2017
Results first posted
Mar 9, 2020
Last update
Mar 9, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 9, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01970540
Lead sponsor
PharmaMar
Responsible party
Sponsor
First posted
Oct 28, 2013
Start date
May 25, 2011
Primary completion
Aug 9, 2017
Completion
Aug 9, 2017
Results posted
Mar 9, 2020
Last update
Mar 9, 2020

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PM 01183

Start the discussion